Regeneron Pharmaceuticals — News Releases Biotech Press Releases — RSS Feed & Live Monitoring
PPN World indexes Regeneron Pharmaceuticals — News Releases press releases and archives each one it distributes. This wire has been quiet since June 25, 2026 — its 3 indexed releases remain searchable, and an alert will tell you the moment it publishes again.
Regeneron Pharmaceuticals — News Releases RSS feed URL
https://investor.regeneron.com/rss/news-releases.xml?items=15About this feed
Regeneron Pharmaceuticals — News Releases is one of the 1000+ press-release feeds PPN World monitors around the clock — an English-language wire focused on Biotech, filed under United States in our country index. Every release is deduplicated, geotagged, and enriched with an AI summary, and you can attach saved-search alerts to any keyword it publishes. The most recent release in our index was published on June 25, 2026; the wire has been quiet since.
How to follow Regeneron Pharmaceuticals — News Releases press releases
- Copy the Regeneron Pharmaceuticals — News Releases RSS feed URL shown above.
- Paste it into any RSS reader (Feedly, Inoreader, NetNewsWire…) to get the raw feed.
- Or track Regeneron Pharmaceuticals — News Releases in PPN World to add deduplication, saved-search alerts, and AI summaries across all 1000+ wires.
Regeneron Pharmaceuticals — News Releases press releases — archive
- Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast18 d ago
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursda…
- Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)22 d ago
Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing FDA accepted NDA under Priority Review with a target a…
- Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO40 d ago
Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE)…
The newest releases on this wire stream live for PPN World members.